Global Tauopathies Treatment Market, by Disease (Frontoyemporal Degeneration (Pick’s Disease, CBD, and PSP), Alzheimer’s Disease, and Other Neurodegenerative Diseases), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 945.5 Million in 2023 and is expected to exhibit a CAGR of 10.0 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The strategies adopted by key market players like acquisitions is expected to drive the global tauopathies treatment market growth over the forecast period. For instance, on January 18, 2023, APRINOIA Therapeutics, a U.S.-based clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer’s disease and Progressive Supranuclear Palsy and Ross Acquisition Corp II, a U.S.-based special purpose acquisition company, announced that they have entered into a definitive agreement. Ross Acquisition Corp II and APRINOIA Therapeutics are combining at an implied fully diluted transaction equity value of US$ 280 million for APRINOIA’s APN-1607, a new generation tau Positron Emission Tomography (PET) tracer with a higher specificity. As part of the business collaboration, Mr. Wilbur L. Ross, Jr., CEO of Ross Acquisition Corp II has personally invested US$ 7.5 million and has committed to provide up to US$ 12.5 million of capital infusion at the closing of the business combination. This funding is intended to meet the capital requirements needed to bring the company’s lead product, 18F-APN-1607, through to commercialization in China.
Global Tauopathies Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems regarding the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global tauopathies treatment market due to reduced screening and service disruptions. For instance, according to survey published by World Health Organization on June 1, 2020, in 155 countries for a 3 week period in May 2020, many people who needed treatment for diseases like cancer, cardiovascular disease, neurological disorders, and diabetes did not receive the health services and medicines they needed since the COVID-19 pandemic began. Public screening programs were also postponed. Postponement was reported in more than 50% of countries. This was consistent with initial WHO recommendations to minimize non-urgent facility-based care whilst tackling the pandemic.
Global Tauopathies Treatment Market: Key Developments
Increasing launch of new drugs that can improve the conditions of people suffering from Alzheimer’s disease is expected to drive the market growth.
For instance, on May 11, 2023, the U.S. Food and Drug Administration (FDA) announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. ‘Agitation’ can include symptoms ranging from pacing or restlessness to verbal and physical aggression. The recommended target dose is 2 mg once daily. The dosage can be increased to the maximum recommended daily dosage of 3 mg once daily after at least 14 days, based on clinical response and tolerability. The supplemental approval of Rexulti was granted to Otsuka Pharmaceutical Company Ltd., a Japan-based healthcare company and Lundbeck Inc., a Denmark-based global pharmaceutical company specialized in brain diseases.
Browse 32 Market Data Tables and 31 Figures spread through 160 Pages and in-depth TOC on Global Tauopathies Treatment Market, by Disease (Frontoyemporal Degeneration (Pick’s Disease, CBD, and PSP), Alzheimer’s Disease, and Other Neurodegenerative Diseases), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/tauopathies-treatment-market-3995
Key Takeaways of the Global Tauopathies Treatment Market:
- The global tauopathies treatment market is expected to exhibit a CAGR of 10 % during the forecast period. Funding raised by U.K. government is expected to accelerate research and development activities. For instance, on November 14, 2021, The National Institute for Health and Care Research, U.K. government’s major funder of clinical, public health, social care, and translational research, committed to invest US$ 408.3 million over the next 5 years. At least US$ 54.4 million will be made available specifically for research to help find a cure for Motor Neurone Disease (MND). The full US$ 408.3 million investment will fund projects into a range of diseases such as Pick's Disease, Fronto-temporal dementia, Wernicke-Korsakoff, Parkinson's disease dementia, Lewy Body dementia, Alzheimer's disease, and mild cognitive impairment, to understand and search for new treatments.
- Among the disease type, the frontoyemporal degeneration segment is expected to dominate the global tauopathies treatment market over the forecast period, owing to the approval of investigational new drugs for the treatment of neurodegenerative condition. For instance, on June 3, 2023, GemVax&KAEL, a South Korea-based biotechnology company specializing in the development of peptide-based new drugs, announced that it has received U.S. FDA approval as Investigational New Drug (IND) of GV1001 for Progressive Supranuclear Palsy (PSP) treatment. The company will conduct the clinical trial at domestic hospitals including Seoul National University Borame Medical Center. GV1001 previously showed statistically significant efficacy in restoring motor ability, spatial cognitive ability, and inhibiting damage to tau protein in animal experiments. GV1001 combines peptides derived from the human enzyme telomerase and is known to have anti-aging, antioxidant, and anti-inflammatory effects. It is a multi-faceted drug candidate expected to improve the brain's immune environment and reduce inflammation in neurodegenerative diseases such as Alzheimer's and PSP.
- Among region, North America is expected to be the dominant region in the global tauopathies treatment market, owing to the increasing research and development activities for tauopathic condition in the region. For instance, on February 20, 2020, the U.S. FDA granted orphan drug designation to RT001 (Retrotope) for the treatment of Progressive Supranuclear Palsy (PSP). RT001 is a first-in-class, oral Deuterated Polyunsaturated Fatty Acid (D-PUFA) that stabilizes mitochondrial and cellular membranes by protecting against reactive oxygen species. The investigational drug prevents lipid peroxidation caused by polyunsaturated fats (PUFAs), which is believed to be the primary source of several degenerative diseases. The designation is supported by preclinical data that demonstrated the ability of RT001 to inhibit lipid peroxidation, thereby protecting mitochondrial function. RT001’s mechanism of action both lowers lipid peroxidation and prevents mitochondrial cell death of neurons which is associated with degenerative diseases onset and progression.
- The major players operating in the global tauopathies treatment market include Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., AB Science, Cortice Biosciences, REGENXBIO Inc., Aquinnah Pharmaceuticals, Neurimmune, Oligomerix, Inc., Biogen, TauRx, Sellas, Catalent Inc., Selvita S.A, Bristol-Myers Squibb Company, Chronos Therapeutics Limited, and SK Biopharmaceuticals Co., Ltd.
